Viewing Study NCT01235260

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:06 AM
Ignite Modification Date: 2026-05-19 @ 8:01 AM
Study NCT ID: NCT01235260
Status: COMPLETED
Last Update Posted: 2016-07-19
First Post: 2010-11-04
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diabetes Mellitus View
None Foot Ulcer View
None Diabetic Foot View
None Diabetic Neuropathies View
Keywords:

Keywords

Keyword Brief Keyword Text View
None REGRANEX (becaplermin) View
None Platelet-derived growth factor BB View
None Cancer View
None Cancer incidence View
None Cancer mortality View
None Lower Extremity Diabetic Neuropathic Ulcer View